top of page

Syndax's CEO talks about the company's two new launches (Revuforj and Niktimvo), both of which are tracking ahead of expectations

  • Sep 8, 2025
  • 1 min read

Michael Metzger describes the uptake of the therapies, both of which were approved in the second half of last year, and highlights a potential new indication (NPM1 mutations) for Revuforj that is in front of FDA right now. Plus, how investors should think about Syndax over the year ahead.




Coverage brought to you by:


Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

​

​Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page